Clinical Research Papers:

The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma

Ying Guan, Anchuan Li, Weiwei Xiao, Shuai Liu, Binbin Chen, Taixiang Lu, Chong Zhao _ and Fei Han

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:33926-33934. https://doi.org/10.18632/oncotarget.5271

Metrics: PDF 1769 views  |   HTML 2352 views  |   ?  


Ying Guan1,2,*, Anchuan Li3,*, Weiwei Xiao1,*, Shuai Liu4, Binbin Chen1, Taixiang Lu1, Chong Zhao1, Fei Han1

1Department of Radiotherapy Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, P. R. China

2Department of Radiation Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Cancer Institute of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China

3Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350009, P. R. China

4Department of Radiotherapy Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Chong Zhao, e-mail: [email protected]

Fei Han, e-mail: [email protected]

Keywords: Endostar, nasopharyngeal carcinoma, recurrence, chemotherapy, intensity-modulated radiotherapy

Received: March 13, 2015     Accepted: September 04, 2015     Published: September 15, 2015


Purpose: To evaluate the short-term efficacy and safety of recombinant human endostatin (Endostar) combined with chemoradiotherapy for the treatment of advanced, locally recurrent nasopharyngeal carcinoma (NPC).

Materials and Methods: Between March 2010 and October 2013, a total of 22 patients with stage rIII-IVb locally recurrent NPC underwent salvage radiotherapy with Endostar in Sun Yat-Sen University Cancer Center. Intensity-modulated radiotherapy (IMRT) was delivered. Platinum-based chemotherapy was used in a neoadjuvant protocol. Endostar was continuously administered intravenously (105 mg/m2) for 14 days (Days 1–14) from the first day of treatment during a 21-day cycle. Tumor response and treatment toxicities were observed.

Results: Until January 2014, the median follow-up time was 13 months (range, 4–41 months). All patients completed the planned radiotherapy. A complete response was achieved in 20 patients, and a partial response was achieved in 2 patients. The incidence of grade 3–5 late radiation injury in this study was 50% (11/22) and that of nasopharyngeal mucosal necrosis was 31.8% (7/22).

Conclusions: Endostar combined with chemoradiotherapy may be effective in decreasing both the incidence of nasopharyngeal mucosal necrosis. Studies with a larger sample size and longer follow-up are warranted.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5271